TRANXENE CAP 3.75MG 3.75 MG
CLORAZEPATE DIPOTASSIUM : 3.75 MG · DIN 00264938 · ABBOTT LABORATORIES, LIMITED
Health Canada status: CANCELLED POST MARKET
What is TRANXENE CAP 3.75MG?
TRANXENE CAP 3.75MG 3.75 MG contains CLORAZEPATE DIPOTASSIUM : 3.75 MG. It is listed in the Health Canada Drug Product Database under DIN 00264938, held by ABBOTT LABORATORIES, LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 01-Aug-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00264938 |
|---|---|
| Brand name | TRANXENE CAP 3.75MG |
| Generic / active ingredient | CLORAZEPATE DIPOTASSIUM : 3.75 MG |
| Manufacturer | ABBOTT LABORATORIES, LIMITED |
| Strength | 3.75 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA05 CLORAZEPATE POTASSIUM |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Aug-2003 |
What can be used instead?
Other Canadian products sharing ATC code N05BA05 CLORAZEPATE POTASSIUM. 3 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLORAZEPATE | 15 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 00860697 |
| CLORAZEPATE | 3.75 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 00860689 |
| CLORAZEPATE | 7.5 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 00860700 |
| NOVO-CLOPATE CAP 15MG | 15 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00628212 |
| NOVO-CLOPATE CAP 3.75MG | 3.75 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00628190 |
| NOVO-CLOPATE CAP 7.5MG | 7.5 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00628204 |
| TRANXENE CAP 15MG | 15 MG | CAPSULE | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00264911 |
| TRANXENE CAP 7.5MG | 7.5 MG | CAPSULE | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00264946 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.